Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global cholera vaccines market was valued at USD 90.5 million in 2024. The market is projected to grow from USD 100.3 million in 2025 to USD 171 million by 2031, exhibiting a CAGR of 9.8% during the forecast period.
Cholera vaccines are biological preparations that provide immunity against Vibrio cholerae, the bacteria causing cholera. These vaccines offer approximately 85% protection against cholera during the first six months post-vaccination, with efficacy declining to 50-62% in the first year. Key vaccine types include Dukoral, Shanchol, and Vaxchora, each with distinct formulations and administration methods.
Market growth is driven by increasing cholera outbreaks in endemic regions, particularly in Africa and South Asia, coupled with rising government initiatives for vaccination programs. The World Health Organization's expanded use of oral cholera vaccines in outbreak control has significantly boosted demand. However, vaccine shortages and cold chain logistics remain persistent challenges. Major players like Valneva SE, Shantha Biotechnics, and PaxVax are actively developing next-generation vaccines to address these limitations while improving thermostability and efficacy.
Increasing Global Cholera Outbreaks
The cholera vaccines market is experiencing growth due to recurrent outbreaks in developing regions. In 2022, over 30 countries reported cholera cases, with Africa and Asia being most affected. Governments and international health organizations are prioritizing vaccination programs as a preventive measure. WHO reports cholera cases have increased by 25% since 2021, creating urgent demand.
Improved Vaccine Formulations
Recent advancements in oral cholera vaccine (OCV) formulations have increased efficacy and reduced dosage requirements. Single-dose vaccines now provide protection for up to 2 years, compared to previous 2-dose regimens. This innovation improves vaccination campaign efficiency in outbreak settings, reducing logistical challenges and increasing coverage rates.
Vaccine supply has doubled since 2020, with Gavi-supported countries receiving 50 million doses in 2023 through the global stockpile
The establishment of emergency vaccine stockpiles by WHO and partners has created a sustainable market for manufacturers while ensuring rapid outbreak response.
MARKET CHALLENGES
Cold Chain Logistics Requirements
Most cholera vaccines require strict temperature-controlled storage and distribution, creating barriers in resource-limited settings. Transportation and storage below 25C adds significant cost to vaccination programs in tropical regions, where cholera is most prevalent.
Other Challenges
Limited Awareness in Endemic Areas
Despite growing immunization efforts, vaccine hesitancy remains a challenge due to misinformation and cultural beliefs about preventive medicine in some cholera-endemic communities.
Priority Competition in Immunization Programs
Cholera vaccination campaigns often compete for funding and implementation capacity with other essential immunization programs (measles, polio, COVID-19). In low-income countries, public health budgets may prioritize diseases with higher mortality rates or pandemic potential over cholera prevention.
Expansion of Mass Vaccination Campaigns
International health initiatives are increasingly incorporating cholera vaccination into routine humanitarian response. The growing adoption of mass vaccination strategies in refugee camps and disaster areas presents significant market expansion potential, with projected campaign coverage increasing by 18% annually through 2025.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Dukoral demonstrates strong market position due to its established efficacy profile and widespread regulatory approvals. Vaxchora shows growing adoption as the only single-dose cholera vaccine approved for travelers, benefiting from increasing international mobility. The market shows preference for orally administered vaccines due to their ease of administration and storage stability. |
| By Application |
|
Emergency Outbreak Response accounts for significant demand, driven by increasing cholera outbreaks in vulnerable regions. Travel Vaccination represents a consistent application segment supported by advisory requirements for visiting endemic areas. The niche for routine immunization shows gradual expansion with growing incorporation into national vaccination programs of high-risk countries. |
| By End User |
|
Public Health Agencies dominate procurement through bulk purchases for immunization campaigns and outbreak responses. Travel Vaccination Centers show consistent demand growth due to increasing international travel to endemic regions. Hospital adoption remains limited primarily to regions with cholera prevalence, while showing potential for expanded utilization in outbreak preparedness strategies. |
| By Distribution Channel |
|
Government Procurement leads as the primary channel through national immunization programs and public health initiatives. The Non-Profit channel plays a critical role in vaccine access for humanitarian operations in crisis zones. Private sector distribution shows growing importance for travel-related vaccinations and corporate health programs. |
| By Administration Route |
|
Oral Vaccines demonstrate overwhelming market preference due to advantages in administration logistics and patient compliance. The oral route shows particular suitability for mass vaccination campaigns in resource-limited settings. While injectable cholera vaccines exist, their utilization remains limited due to higher complexity in administration and cold chain requirements. |
Global Cholera Vaccine Market Dominated by Established Pharmaceutical Giants
The cholera vaccines market is characterized by the presence of several key pharmaceutical players, with Shantha Biotechnics (a Sanofi company) and Valneva SE leading through their Shanchol and Dukoral products respectively. These companies benefit from extensive distribution networks and WHO prequalification status, allowing them to serve both endemic regions and travelers. The market structure remains moderately concentrated, with the top five players accounting for approximately 68% of total vaccine revenue in 2023.
Emerging biotech firms like PaxVax (acquired by Emergent BioSolutions) and Bharat Biotech have introduced innovative oral cholera vaccine formulations, creating competitive pressure on traditional manufacturers. Strategic partnerships with global health organizations like GAVI and UNICEF remain crucial for market penetration in high-risk regions such as Sub-Saharan Africa and South Asia.
List of Key Cholera Vaccines Companies ProfiledGlaxoSmithKline plc (GSK)
PaxVax, Inc. (Emergent BioSolutions)
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
EuBiologics Co., Ltd.
Hilleman Laboratories
Bio Farma
Serum Institute of India
Beijing Tiantan Biological Products
Prokarium Ltd.
The global cholera vaccines market has shown significant growth, valued at $90.5 million in 2024 with projections reaching $171 million by 2031 at a CAGR of 9.8%. This expansion is primarily fueled by rising cholera outbreaks in developing regions, particularly in Sub-Saharan Africa and South Asia where inadequate sanitation infrastructure persists. The vaccines provide 85% protection during the first six months, decreasing to 50-62% in the first year, demonstrating substantial effectiveness in outbreak control.
Other TrendsExpanding Vaccine Pipeline with Novel Formulations
Major pharmaceutical companies like Valneva SE and Takeda Pharmaceutical are actively developing next-generation oral cholera vaccines with improved thermostability and longer-lasting immunity. Currently, Dukoral, Shanchol, and Vaxchora dominate the market, capturing over 75% of global revenue share. Emerging formulations in clinical trials show promise for single-dose regimens with extended protection periods beyond three years.
Increasing Government and NGO Procurement ProgramsPublic sector initiatives account for 68% of vaccine procurement, with WHO-led vaccination campaigns in endemic regions driving demand. The global vaccine stockpile distributed over 35 million doses in 2023 alone. Gavi, the Vaccine Alliance has committed $120 million toward cholera vaccine acquisition and distribution through 2025, creating stable demand for manufacturers.
Regional Market Disparities in Access and Adoption
While Asia-Pacific represents 42% of the cholera burden, Africa accounts for 58% of vaccine consumption due to active outbreak response programs. North America and Europe primarily consume vaccines for traveler's prophylaxis, representing only 7% of the total market volume. Latin America shows growing adoption with Brazil initiating national vaccination programs in high-risk areas.
Strategic Collaborations Shaping Competitive LandscapeMajor players like Shantha Biotechnics and GlaxoSmithKline are forming partnerships with local manufacturers in endemic countries to improve production capacity and reduce costs. The market remains concentrated, with the top five companies holding 82% revenue share. Recent mergers, such as Emergent BioSolutions' acquisition of PaxVax, demonstrate ongoing industry consolidation.
Regional Analysis: Cholera Vaccines MarketAfrica
Sub-Saharan Africa represents a high-growth market for cholera vaccines, with recurring outbreaks across many nations. Countries like Zimbabwe, Nigeria, and the Democratic Republic of Congo frequently experience severe cholera epidemics. Humanitarian organizations play a critical role in vaccine distribution during outbreaks, supported by WHO stockpiles. Limited healthcare infrastructure challenges vaccination efforts, though emergency response campaigns achieve good coverage. The region shows increasing adoption of oral vaccines over injectable alternatives. Climate-related concerns suggest growing future demand as cholera patterns shift with environmental changes.
Latin America
Latin America maintains moderate cholera vaccine demand centered in Haiti and recently affected areas. Haiti's post-earthquake cholera epidemic established long-term vaccination needs through targeted immunization programs. Other countries implement preventive vaccination in high-risk zones. Regional production capacity remains limited, requiring imports from Asian manufacturers. Tourism industry concerns drive some private sector vaccination initiatives in coastal resorts. Government-health organization partnerships focus on outbreak prevention through improved surveillance and rapid response vaccination.
Middle East
The Middle East shows variable cholera vaccine demand concentrated in conflict-affected areas like Yemen and refugee populations. War-induced infrastructure damage creates cholera risks addressed through humanitarian vaccination programs. Gulf states implement preventive measures for pilgrims and foreign workers. Limited local disease incidence reduces routine vaccination needs in most countries. Imported cases occasionally trigger localized vaccination campaigns. The market remains opportunity-driven rather than consistent across the region.
North America & Europe
Developed markets demonstrate minimal routine cholera vaccine demand, primarily serving travelers to endemic regions. Specialty travel clinics and military applications constitute the primary market segments. Vaccine stockpiling for emergency response contributes to regional demand fluctuations. Stringent regulatory requirements limit market entrants. Growing immigrant populations maintaining ties to endemic countries create niche vaccination needs. Research investments focus on next-generation vaccine development rather than commercial market expansion.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global cholera vaccines market was valued at USD 90.5 million in 2024 and is expected to reach USD 171 million by 2031.
Which key companies operate in Global Cholera Vaccines Market?
-> Key players include Shantha Biotechnics, PaxVax, Valneva SE, Merck, and GlaxoSmithKline, among others.
-> Key growth drivers include increasing cholera outbreaks and government vaccination initiatives in endemic regions.
-> Africa remains the dominant region due to high disease prevalence, while Asia-Pacific shows rapid growth.
-> Emerging trends include development of thermostable vaccines and next-generation oral cholera vaccines with improved efficacy.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates